cyproterone and Alopecia

Topics: Acne Vulgaris; Adolescent; Adrenal Hyperplasia, Congenital; Adult; Alopecia; Androgens; Cyproterone; Cyproterone Acetate; Female; Hair; Hirsutism; Humans; Male; Polycystic Ovary Syndrome; Racial Groups; Sex Characteristics; Stress, Psychological; Syndrome

Topics: Acne Vulgaris; Adrenal Gland Neoplasms; Alopecia; Androgen Antagonists; Androgens; Cyproterone; Female; Hirsutism; Humans; Pregnancy; Sex Differentiation; Virilism

Topics: Acne Vulgaris; Alopecia; Animals; Bone Development; Cyproterone; Female; Fertility; Hirsutism; Humans; Libido; Male; Prostate; Prostatic Hyperplasia; Prostatic Neoplasms; Puberty; Sebaceous Glands; Seminal Vesicles; Sex Differentiation; Skin; Testis

Topics: Alopecia; Anabolic Agents; Androgens; Chlormadinone Acetate; Contraceptives, Oral; Cyproterone; Estrogens; Female; Gonadal Steroid Hormones; Hirsutism; Humans; Hypertrichosis; Male

Topics: Acne Vulgaris; Alopecia; Androgen Antagonists; Bone Development; Cyproterone; Female; Growth; Hirsutism; Humans; Hypertrichosis; Libido; Male; Prostate; Prostatic Neoplasms; Puberty, Precocious; Seminal Vesicles; Sexual Dysfunction, Physiological; Skin

Topics: Alopecia; Androgen Antagonists; Contraceptives, Oral; Cyproterone; Ethinyl Estradiol; Female; Hair; Hirsutism; Humans; Nandrolone; Pregnancy; Pregnancy Complications

Low-dose hormonal contraceptives with specifically reduced estrogen are now the drug of choice for the prevention of internal risks. The antiandrogenic hormonal contraceptives have also had to be adapted to this situation. In a study involving 144 women, most of whom were suffering from moderately severe androgenization, Diane-35 (reduced to 0.035 mg ethinyl estradiol) was used as an antiandrogenically active hormonal contraceptive. From the sixth treatment cycle onward acne and seborrhea were significantly improved or already healed. In the 12th treatment cycle the treatment success rate was almost 90%. The side effects occurring with higher-dose hormonal contraceptives were reduced, cycle behavior was acceptable, and the incidence of metrorrhagia corresponded to that found with other micropills.

Topics: Acne Vulgaris; Adult; Alopecia; Androgen Antagonists; Clinical Trials as Topic; Contraceptives, Oral, Hormonal; Cyproterone; Cyproterone Acetate; Dermatitis, Seborrheic; Drug Combinations; Ethinyl Estradiol; Female; Hirsutism; Humans; Menstrual Cycle; Middle Aged

Treatment of virilization symptoms in 230 patients is reported. 68 patients were treated with Planovin (4 mg megestrol acetate and .05 mg ethinyl estradiol), 77 with SH81041 (100 mg Cyproterone acetate for 10 days and .05 mg ethinyl estradiol for 21 days), and 85 were treated first and Planovin and then with SH81041. Acne, seborrhea, hirsutism, and alopecia improved under treatment with each preparation; results were similar with acne and alopecia, while SH81041 was somewhat more effective than Planovin in treating seborrhea and hirsutism. Therapeutic results obtained during treatment with SH81041 in acne and alopecia are retained during Planovin treatment, but seborrhea and hirsutism become worse again. Successful treatment was independent of the severity of hirsutism and the duration of of treatment. Side effects included breakthrough bleeding and sweating.

Topics: 17-Ketosteroids; Acne Vulgaris; Adolescent; Adult; Alopecia; Androgen Antagonists; Clinical Trials as Topic; Cyproterone; Dermatitis, Seborrheic; Ethinyl Estradiol; Female; Hirsutism; Humans; Megestrol; Virilism

The multiplicity of meningiomas or abrupt lesion growth in patients treated with cyproterone acetate suggests that this progestative treatment may promote lesion growth. We report the rapid regression of an incidental meningioma after discontinuation of a 10-year cyproterone acetate treatment. This unique observation suggests that conservative management of meningiomas may be the best option among users of high doses of cyproterone acetate, given that spontaneous regression may occur after hormonal treatment discontinuation.

Topics: Alopecia; Androgen Antagonists; Cyproterone; Female; Humans; Magnetic Resonance Imaging; Meningeal Neoplasms; Meningioma; Middle Aged; Remission Induction

Acne, androgenogenetic alopecia, hyperseborrhea and hirsutism may result from hyperandrogenism in women. This may be peripheral "idiopathic" hyperandrogenism due to cutaneous metabolism of steroids, but in some cases hyperandrogenism is due to abnormal production or input of steroids with androgenic activity (hyperplasia, endocrine tumors, cysts, consumption of progestogens or other hormones with androgenic activity, menopause...). An assessment is useful only in cases of acne or alopecia if they are accompanied by other signs of peripheral hyperandrogenism and/or disturbed menstruation. The treatment is based on the administration of an anti-androgen (in France, usually cyproterone acetate), combined with other local or systemic treatments for the problem, depending on the age, dermatological signs and context.

Topics: Acne Vulgaris; Adolescent; Adult; Alopecia; Androgen Antagonists; Androgens; Cyproterone; Cyproterone Acetate; Dermatologic Agents; Female; Humans; Male; Menopause; Sex Factors

In a group of healthy, non-vegetarian females currently being treated for diffuse androgen-dependent alopecia with 50 or 100 mg of oral cyproterone acetate for 11 days and 30 or 40 micrograms of ethinyl oestradiol for 20 days of the menstrual cycle, significant decreases in mean serum vitamin B12 (P less than 0.0001), haemoglobin (P less than 0.003) and haematocrit (P less than 0.004) values, were observed after 6 months. Serum folic acid, red-cell folate and mean cell volume remained unchanged within the normal range during this time. All patients responded to oral cyanocobalamin, or intramuscular injections of hydroxocobalamin. In patients with baseline serum vitamin B12 levels below 350 ng/l, we would suggest prophylactic cyanocobalamin concurrent with cyproterone-acetate-ethinyl-oestradiol (CPA EE2) therapy. Studies involving other dose regimens of CPA EE2 (Dianette) or cyproterone acetate alone (Androcur, Cyprostat), may require evaluation of the vitamin B12 status if treatment is to be given for periods of longer than 3 months.

Topics: Administration, Oral; Alopecia; Androgen Antagonists; Cyproterone; Cyproterone Acetate; Drug Therapy, Combination; Ethinyl Estradiol; Female; Humans; Vitamin B 12

Twenty female patients suffering from androgenetic alopecia were treated during one year with 50 micrograms ethinyloestradiol plus 2 mg cyproterone acetate and additional 20 mg cyproterone acetate on days 5-20 of the menstrual cycle. The control group consisted of eight untreated female patients with androgenetic alopecia. The parameters used to evaluate therapeutic results were trichogram, hair shaft diameter of full anagen and number of hairs measuring less than 40 microns. Hair roots were epilated from two locations of the scalp: fronto-cranial and left temporal (reference point). The trichogram of the fronto-cranial scalp region showed an increase of anagens as well as a decrease of telogens. These changes were statistically highly significant. Further, there was a decrease of dysplastic/dystrophic forms. The left temporal scalp region showed no significant differences. The mean hair shaft diameter of full anagen (n = 8) increased, while the number of hairs measuring less than 40 microns (n = 8) decreased. The last two findings showed no statistically significant differences. The therapeutic results warrant the conclusion that cyproterone acetate seems to be effective in androgenetic alopecia in women.

Topics: Adolescent; Adult; Alopecia; Cyproterone; Cyproterone Acetate; Ethinyl Estradiol; Female; Hair; Humans

Topics: Acne Vulgaris; Adolescent; Adult; Alopecia; Androgen Antagonists; Androgens; Cyproterone; Cyproterone Acetate; Drug Combinations; Drug Evaluation; Ethinyl Estradiol; Female; Follow-Up Studies; Hirsutism; Humans

Modes of action of antiandrogens, their side effects as well as indications for their application to androgen-dependent skin conditions. Particular attention is paid to the possibilities for topical medication with antiandrogenic active substances.

Topics: Acne Vulgaris; Alopecia; Androgen Antagonists; Chlormadinone Acetate; Cyproterone; Cyproterone Acetate; Dermatitis, Seborrheic; Drug Therapy, Combination; Female; Hirsutism; Humans; Male; Skin Diseases; Spironolactone

Topics: Adolescent; Adult; Alopecia; Androgen Antagonists; Cyproterone; Cyproterone Acetate; Drug Therapy, Combination; Ethinyl Estradiol; Female; Hormones; Humans

Although one can reasonably infer that antiandrogens are likely to have a marked negative impact on female sexual responsiveness, the side effects of cyproterone acetate (CPA) treatment in hirsute women have been neglected in previous studies. The purpose of this study was to investigate the psychosexual situation of 61 hirsute women before and under hormonal treatment. 21% of the hirsute women were diagnosed as having been sexually dysfunctional before starting hormonal treatment. 44% of the women under antiandrogen treatment reported that their sexual enjoyment was impaired due to the hormonal treatment. Taking into account only those women living in a stable partnership, the percentage goes up to 61%. The conclusion from these results is to give a more detailed account of the possible side effects to the women involved in CPA treatment.

Topics: Acne Vulgaris; Adult; Alopecia; Cyproterone; Cyproterone Acetate; Drug Therapy, Combination; Ethinyl Estradiol; Female; Hirsutism; Humans; Libido; Sexual Behavior

A male volunteer with frontal alopecia was treated simultaneously with 20 mg cyproterone acetate and 5 mg minoxidil topically (daily). During treatment with both drugs, new hair growth was observed on the alopecic scalp. The new hair was lost after discontinuing minoxidil treatment, although cyproterone acetate treatment was continued.

Topics: Adult; Alopecia; Androgen Antagonists; Cyproterone; Cyproterone Acetate; Drug Therapy, Combination; Humans; Male; Minoxidil; Pyrimidines

Management of hirsutism with high-dose oral cyproterone acetate (CPA) is associated with a failure rate of about 30%. The present investigation analyses the efficacy of parenteral CPA administration in non-tumorous hyperandrogenism. Medium-dose CPA (300 mg) was injected intramuscularly once per month, followed by oral ethinylestradiol (40 micrograms daily) for 21 days in 42 patients (total of 293 treatment cycles). The onset of withdrawal bleeding was 3 to 8 days later. This regimen was used as primary therapy (group A; n = 18) as well as follow-up therapy in low-dose (group B; n = 10) and high-dose oral standard CPA failures (group C; n = 14). The following satisfactory or good response rates were observed in regard to hirsutism: group A 83,5%, group B 100%, group C 57%; seborrhea A and B 100%, C 89%; acne and androgenetic alopecia A and B and C 100%. Clinical side effects occurred in 20 patients; they corresponded in type and frequency to those elicited by the high-dose oral standard medication and resulted in termination of treatment in only 3 patients. Pilot studies regarding the pharmacokinetics of CPA as well as the effects on plasma total and free testosterone and prolactin failed to explain the therapeutic superiority of parenteral CPA (n = 7 women). Still, it may be concluded that intramuscular CPA administration represents a new and highly effective means of managing hirsute females.

Topics: Acne Vulgaris; Adult; Alopecia; Cyproterone; Delayed-Action Preparations; Dermatitis, Seborrheic; Female; Hirsutism; Humans; Injections, Intramuscular; Prolactin; Testosterone

We report on 20 female patients suffering from acne, seborrhea, hirsutism, and androgenic alopecia during the years 1980-1982 who have been treated with 1 tablet of Androcur 10 (10 mg cyproteronacetate) daily, in the first 15 days applied together with Diane (0,05 mg ethinylestradiol and 2 mg cyproteronacetate). The results achieved after 2 years show an improvement of acne in 80 per cent of the cases, of seborrhea in 95 per cent, and of both hirsutism and androgenic alopecia in 45 per cent each. So this therapy takes its important place between the therapy with Diane alone and the usual supplementary dosis of 50 mg cyproteronacetate (Androcur) daily.

Topics: Acne Vulgaris; Adolescent; Adult; Alopecia; Androgen Antagonists; Cyproterone; Cyproterone Acetate; Dermatitis, Seborrheic; Drug Combinations; Drug Therapy, Combination; Ethinyl Estradiol; Female; Hirsutism; Humans; Middle Aged; Virilism

Function of the pituitary-adrenal axis was assessed in 16 adult female patients who had been taking cyproterone acetate for greater than 1 year. Some evidence of reduced basal cortisol output was seen in 25% of the patients, but plasma cortisol levels could be stimulated both by hypoglycaemia and by direct corticotrophin (ACTH) stimulation. The latter effect was confirmed by analysis of steroid excretion in urine although basal excreation rates indicated extensive adrenal suppression. These results suggest that cyproterone acetate does have some glucocorticoid activity which is able partially to suppress the pituitary--adrenal axis, but leaves it still responsive to stress.

Topics: Adult; Alopecia; Cyproterone; Cyproterone Acetate; Female; Hirsutism; Humans; Hydrocortisone; Pituitary-Adrenal Function Tests; Pituitary-Adrenal System

It has been established that, through skin responds to circulating androgens, it can also produce androgens from precursors. Therapy can address either of the two following physiopathological steps: the secretory step can be countered by replacement or suppressive therapy which is now fairly well mastered; the target-organ step opens new possibilities concerning receptor abnormalities and receptor control. The medical literature was reviewed for data on hormonal therapy for women with acne, idiopathic hirsutism and seborrheic alopecia, three conditions which are usually only partially improved by cosmetic treatment.

Topics: Acne Vulgaris; Alopecia; Androgen Antagonists; Androgens; Cyproterone; Dermatitis, Seborrheic; Estrogens; Female; Glucocorticoids; Hirsutism; Hormones; Humans; Progesterone; Skin; Spironolactone

Cyproterone acetate acts as an antiandrogen through competitive inhibition of the androgens at cellular level on the peripheral effectors. Associated with ethynyl estradiol potentiates its action upon the cutaneous effectors, and at the same time has a potent ovulostatic action. Forty one women with seborrhea, acne, hirsutism and androgenic alopecia were treated. In 18 cases serum testosterone level were measured by radioimmunoassay before treatment. Most had levels above the normal range. In 7 cases testosterone level were repeated during treatment. Some did not show changes, but in most testosterone plasma increased. Most of the cases with acne and seborrhea showed a definite improvement between 3 and 6 months. Alopecia and hirsutism needed a longer treatment and the results were not so satisfactory. The tolerance was excellent and the side effects were those usually found with other oestrogens and gestagens associations. No rebound was observed when the medication was discontinued, although most of the cases showed a tendency to mild recurrence.

Topics: Acne Vulgaris; Adolescent; Adult; Alopecia; Androgen Antagonists; Cyproterone; Cyproterone Acetate; Dermatitis, Seborrheic; Drug Combinations; Ethinyl Estradiol; Hirsutism; Humans; Hydrocortisone; Middle Aged; Testosterone

Topics: Age Factors; Alopecia; Cyproterone; Female; Humans; Sex Factors

Hormonal influences give rise to hirsutism and may encourage the appearance of seborrhea, acne and falling hair. Androgenically active processes in the cells of the end organs (e. g. sebaceous glands, hair roots) and in the endocrine regulation center may also be responsible for androgenic manifestations in women such as excretion of androgens by suprarenals and ovaries as well as its metabolization and final elimination. The central inhibiting effects of large doses of estrogen or gestagen have been taken advantage of since the sixties with varying therapeutic success. Advances in the treatment were only brought by the development of antiandrogenic progestogens and finally the synthesis of the "antiandrogen" cyproterone acetate in particular which, when selectively applied with critical consideration of the clinical symptoms, brings about a satisfactory therapeutic result for the cosmetically sensitive woman.

Topics: Acne Vulgaris; Alopecia; Binding, Competitive; Chlormadinone Acetate; Cyproterone; Estrogens; Female; Hirsutism; Humans; Megestrol; Progesterone; Receptors, Androgen

The use of antiandrogens (principally cyproterone acetate CPA) to treat women with symptoms of hypersecretion of androgens is discussed. Several therapy schemata are presented. A high dosage "reverse sequential" therapy of 100 mg CPA on the 5th-14th days of the menstrual cycle and 40 mcg ethinyl estradiol (EE) on the 5th-25th days is used in severe cases. Low dosage (2mg CPA, 50 mcg EE) preparations are used for light cases of androgen hypersecretion. Parenteral application of 300 mg CPA per cycle with supplementary EE administration has also been tested. Hirsuitism is treated with good results in 65%-80% of those who use high dosage preparations and 50% of those who use the low dosage preparations. The effects of the therapy are apparent 9-12 months after it begins; the therapy is not as successful among patients whose problems are not related to their hormonal balance. Seborrhea and endogenous acne can be effectively treated with all types of antiandrogen preparations. Androgenetic alopecia can also be treated in a majority of cases with CPA preparations. CPA treatment should not last longer than 12 months. High dosage CPA use by ovulating women causes suppression of the preovulatory LH and FSH peaks but has little effect on basal levels; in postmenopausal women, the basal LH and FSH levels are significantly reduced. Use of CPA by itself causes a significant decrease in the levels of testosterone and delta-4-andostendion 3,17-dion. Use of CPA/EE combinations causes an increase in SHBG and the blood cortisol levels. Protein metabolism, hematopoesis, blood coagulation, and liver function are not affected by CPA use. Reduced glucose utilization and an increase in triglyceride levels are observed during CPA use. Pregnant women and women over 40 or with androgen-producing tumors should not use CPA.

Topics: Acne Vulgaris; Adrenocorticotropic Hormone; Alopecia; Androgen Antagonists; Cyproterone; Cyproterone Acetate; Dermatitis, Seborrheic; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ethinyl Estradiol; Female; Follicle Stimulating Hormone; Hirsutism; Humans; Hypertrichosis; Luteinizing Hormone; Pregnancy; Prolactin; Virilism

Cyproterone acetate, combined with ethinyl estradiol, was administered to 60 women (mean age: 25 years) suffering from hirsutism, acne and alopecia for 3--39 months. The rate of success was 94% for acne, 85% for hirsutism and 55% for alopecia. These results are comparable to those already reported. No correlation was found between the degree of the disease or plasma levels of testosterone, androstenedione, respectively urinary 17-cetosteroids, and the effectiveness of the treatment. Side effects were rare and identical in frequency and nature to those encountered during treatment with estrogen-containing contraceptives.

Topics: 17-Ketosteroids; Acne Vulgaris; Adult; Alopecia; Androstenedione; Cyproterone; Female; Hirsutism; Humans; Testosterone

101 hirsute women received Diane, a combination of 2 mg cyproterone acetate and 50 micrograms ethinyl oestradiol per capsule, from the fifth to twenty-fifth day during a total of 1105 cycles. The treatment was satisfactory in 96% of women with acne, 84% with androgenic alopecia, 79% with seborrhoea, and 50% of those with mild or moderate hirsutism. The effectiveness of treating hirsutism or alopecia depended on its severity and duration. There was no correlation between various measures of androgen levels before and during treatment and the clinical results. Side effects were similar to those after contraceptive one-phase preparations, both in kind and incidence. None of the women became pregnant. Diane is thus the drug of choice in hormonal contraception of patients with acne, seborrhoea, androgenic alopecia or mild hirsutism. It is also suitable in the follow-up or interval management of high-dose cyproterone acetate treatment of severe hirsutism, in order to maintain the effect obtained with lower hormone doses.

Topics: Acne Vulgaris; Alopecia; Contraception; Cyproterone; Dermatitis, Seborrheic; Ethinyl Estradiol; Female; Hirsutism; Humans

Topics: Acne Vulgaris; Alopecia; Cyproterone; Dermatitis, Seborrheic; Female; Hirsutism; Humans; Virilism

In spite of remarkable therapeutic results obtained by gestagens with antiandrogenic activity, usually combined with estrogen, in oily seborrhea, acne, Fox-Fordyce disease, androgenetic alopecia and hirsutism many dermatologist still hesitate to treat the named disorders by hormones. The reason for their hesitation appears to be the erroneous belief, that the named disturbances represent hormonal disorders the treatment of which does not belong to dermatology. After a survey on the mechanism of action of antiandrogens the basic difference between androgen dependent skin disorders and endocrinopathies with manifestation on the skin and its appendages is explained. Androgen dependent skin disorders, like oily seborrhea and most cases of acne are not the result of endocrine disturbances in the sense of an pathologically increased or decreased production of sexual hormons. Administering sexual hormons the physician takes advantage of the sebosuppressive effect of female sexual hormons as he does of the antiallergic activity of the hormon cortisol (and related compounds) in the treatment of eczemas. The antiandrogenic treatment of androgenetic alopecia, hirsutism and androgenetic acne--with their underlying hormonal disturbance, consisting in an increased production of androgens, represents an quasi etiological therapy. As in these cases the hormonal disturbances finds its expression mainly or exclusively in disorders of the skin or hair growth, the dermatologist, preferentially in cooperation with endocrinogists and/or gynacologists remains entitled to take over the treatment. The available drugs are discussed and suggestions are made for their appropriate use.

Topics: Acne Vulgaris; Alopecia; Androgen Antagonists; Chlormadinone Acetate; Cyproterone; Dermatitis, Seborrheic; Female; Hirsutism; Humans; Miliaria; Progesterone

The etiology of male-pattern alopecia is explained as an interrelationship of three factors, genetic--a single dominant sex-limited gene; endocrine--dihydrotestosterone is the specific hormone responsible; and age. Other factors previously used to explain male-pattern alopecia are debunked. Treatment today is directed in the area of endocrinology, basically using either antiandrogens that block 5-alpha-reductase, thus preventing the formation of dihydrotestosterone, or steroids that interfere with dihydrostestosterone cytosol--nuclear binding protein expression.

Topics: Adult; Age Factors; Alopecia; Cyproterone; Humans; Hydroxytestosterones; Male; Middle Aged; Progesterone

Topics: Acne Vulgaris; Adolescent; Adult; Alopecia; Child; Chlormadinone Acetate; Cyproterone; Dermatitis, Seborrheic; Female; Fertility; Hirsutism; Humans; Menstruation; Puberty, Precocious; Skin Diseases

The paper refers to 167 patients who were treated with 2 mg Cyproteronacetate and 50 mug Ethinyloestradiol because of acne, seborrhoea, hirsutism and androgenetic alopecia. The application was daily from the 5th to the 25th day of cycle over a period of 12 months. The success of treatment depended on the severity of virilisation: in cases of light acne only 77% of the patients showed improvement, while in cases of severe acne 91,4% showed improvement or healing of acne. The corresponding figures for seborrhoea were 55,7% and 89,4% respectively, and for hirsutism 37,4% and 60,9% respectively. Furthermore the success of treatment of the different virilising symptoms depended on the duration of therapy: while acne was already cured significantly after 6 months of treatment, seborrhoea and hirsutism show continuous improvement up to the 10th month thetherapy. Concerning side effects during therapy spottings and brake through bleedings were registered in 17,1 and 6% of cycles respectively. 16,2% of the patients noted breast tensions. Finally 68,7% of the patients suffered from nervousness, a very subjective symptom, which might be explained by the psychic lability accompanying virilising symptoms. The drop out rate was 7,8%, being not higher than with other oral contraceptives.

Topics: Acne Vulgaris; Alopecia; Cyproterone; Dermatitis, Seborrheic; Ethinyl Estradiol; Female; Hirsutism; Humans; Menstruation Disturbances; Time Factors; Virilism

Topics: Acne Vulgaris; Adolescent; Adult; Alopecia; Androgen Antagonists; Cyproterone; Dermatitis, Seborrheic; Drug Combinations; Drug Therapy, Combination; Ethinyl Estradiol; Female; Hirsutism; Humans; Middle Aged

The different side effects of synthetic progestins used in oral contraceptives offer the possibility of avoiding undesired side effects and accentuating desired ones. Based on our clinical studies with antiandrogens (cyproterone acetate) selection of an oral contraceptive with antiandrogenic side effects for women with virilization phenomena (acne, seborrhea oleosa) is proposed. These women should at least not be treated with gestagens which have androgenic side effects, such as nortestosterone derivatives. Women suffering from severe acne, androgenic alopecia, or idiopathic hirsutism should be treated with higher doses of antiandrogens.

Topics: Acne Vulgaris; Alopecia; Androgen Antagonists; Contraceptives, Oral; Contraceptives, Oral, Hormonal; Cyproterone; Female; Hirsutism; Humans; Pregnancy; Progesterone Congeners; Virilism

Twenty-five female patients, aged 14 to 49, and suffering from syptoms of virilization (hirsutism, acne, seborrhea and alopecia) were treated with an estrogen-progestogen combinantion, i.e. cyproterone acetate and ethinylestradiol, having antiandrogenic and antiovulatory action. Patients were submitted to monitoring by means of a series of laboratory tests in order to detect any toxic or hormonal effects that might occur. In most cases symptoms of virilization were significantly reduced, while untoward side effects were not noted.

Topics: Acne Vulgaris; Adolescent; Adult; Alopecia; Cyproterone; Dermatitis, Seborrheic; Drug Combinations; Ethinyl Estradiol; Female; Hirsutism; Humans; Middle Aged; Virilism

Topics: Acne Vulgaris; Adolescent; Adult; Alopecia; Chlormadinone Acetate; Contraceptives, Oral; Cyproterone; Dermatitis, Seborrheic; Drug Combinations; Drug Evaluation; Ethinyl Estradiol; Female; Follow-Up Studies; Hirsutism; Humans; Megestrol; Mestranol; Nandrolone; Norethindrone; Norgestrel

Topics: Acetates; Acne Vulgaris; Alopecia; Cyproterone; Dermatitis, Seborrheic; Drug Therapy, Combination; Ethinyl Estradiol; Female; Hirsutism; Humans; Time Factors

Topics: Acne Vulgaris; Alopecia; Androgen Antagonists; Animals; Chlormadinone Acetate; Cyproterone; Dermatitis, Seborrheic; Female; Hirsutism; Humans; Male; Progestins; Rats; Time Factors

Topics: Acne Vulgaris; Adult; Alopecia; Animals; Breast Neoplasms; Chlormadinone Acetate; Contraception; Contraceptives, Oral; Contraceptives, Postcoital; Cyproterone; Delayed-Action Preparations; Dermatitis, Seborrheic; Dogs; Estrogens; Ethinyl Estradiol; Female; Hirsutism; Humans; Injections, Intramuscular; Norgestrel; Progestins

Topics: Adult; Alopecia; Androgen Antagonists; Cyproterone; Drug Combinations; Ethinyl Estradiol; Female; Humans; Pregnadienes